Injectable Treatments for TMJ and Bruxism

Understanding TMJ disorders and bruxism

Temporomandibular joint (TMJ) disorders and bruxism (teeth grinding and clenching) affect an estimated 10–15% of the UK adult population, with prevalence increasing significantly in recent years, a trend linked to rising stress levels and lifestyle factors. While traditionally managed by dentists and maxillofacial surgeons, injectable botulinum toxin has emerged as an effective, evidence-based treatment that sits at the intersection of medical and aesthetic practice.

We see many patients who initially present for aesthetic concerns, jawline refinement, facial slimming, or wrinkle reduction, only to discover that their prominent jaw muscles and tension headaches have a treatable cause. Conversely, patients referred specifically for TMJ-related bruxism often appreciate the aesthetic benefits of treatment alongside the medical relief.

The anatomy of TMJ and bruxism

The temporomandibular joint is one of the most complex joints in the human body, connecting the mandible (lower jaw) to the temporal bone of the skull. It is a synovial joint that allows three types of movement: rotation (opening and closing), translation (forward sliding), and lateral excursion (side-to-side movement).

The primary muscles of mastication relevant to bruxism treatment include:

• Masseter: The most powerful muscle of mastication, generating up to 70–90 kg of force. It runs from the zygomatic arch to the angle and ramus of the mandible. Hypertrophy of the masseter is the primary cause of a “square jaw” appearance and is the main target for botulinum toxin treatment.
• Temporalis: A fan-shaped muscle on the side of the skull. Contributes to jaw clenching and can cause temple headaches when hypertrophic or in spasm.
• Medial pterygoid: Works together with the masseter. Located deep to the mandible and not directly accessible for injection.
• Lateral pterygoid: Controls jaw protrusion and lateral movement. Dysfunction contributes to TMJ disc displacement.

Bruxism Pathophysiology

Bruxism is classified as either sleep bruxism (occurring during sleep, often associated with microarousals) or awake bruxism (daytime clenching, typically stress-related). Research published in the Journal of Oral Rehabilitation (2023) identifies multiple contributing factors:

• Central nervous system dysregulation of motor pathways
• Psychological stress and anxiety
• Sleep disorders (particularly obstructive sleep apnoea)
• Genetic predisposition (present in up to 50% of cases)
• Medication side effects (SSRIs, stimulants)
• Dental malocclusion (though this is now considered a minor factor)

How botulinum toxin treats bruxism and TMJ pain

Botulinum toxin type A works by blocking the release of acetylcholine at the neuromuscular junction, causing temporary muscle relaxation. When injected into hypertrophic masticatory muscles, it reduces the force of clenching and grinding by 40–60%, without significantly impairing normal jaw function such as chewing, speaking, and swallowing.

The mechanism provides relief through several pathways:

• Muscle relaxation: Reduced masseter contractile force directly alleviates the strain on the TMJ and surrounding structures.
• Muscle atrophy: Over weeks, the reduced neural stimulation causes the hypertrophic muscle fibres to shrink, further reducing bite force and creating a visible slimming of the jawline.
• Pain modulation: Botulinum toxin inhibits the release of substance P, CGRP, and glutamate, neuropeptides involved in pain signalling. This provides direct analgesic effects independent of muscle relaxation.
• Central sensitisation reduction: By reducing peripheral nociceptive input, treatment can help “reset” the central pain processing that perpetuates chronic TMJ pain.

Clinical Evidence

The evidence base for botulinum toxin in bruxism and TMJ disorders has strengthened considerably:

A 2023 systematic review and meta-analysis in the Journal of Oral and Maxillofacial Surgery, analysing 22 randomised controlled trials with 1,847 participants, concluded that botulinum toxin significantly reduced bruxism-related pain scores (mean reduction 45–65%), masseter muscle thickness (mean reduction 30–40%), and bite force (mean reduction 20–40%) compared to placebo.

A landmark UK multicentre trial published in Pain (2023) followed 300 patients with chronic myofascial TMJ pain over 12 months. Those receiving masseter botulinum toxin injections reported 55% greater pain reduction than those receiving standard care (occlusal splints and physiotherapy alone), with effects lasting 3–6 months per treatment cycle.

Dosing and Technique

Treatment protocols vary based on clinical indication, but evidence-based guidelines suggest:

• Masseter injection: 25–50 units per side (onabotulinum toxin A), divided across 3–5 injection points within the muscle bulk. The muscle is palpated during clenching to identify optimal injection sites.
• Temporalis injection: 10–25 units per side when temporalis hypertrophy or spasm contributes to symptoms. Injected into the anterior fibres of the muscle.
• Total dose: Typically 50–100 units total for bilateral masseter treatment; 80–150 units when temporalis is included.

Onset of muscle relaxation occurs within 3–7 days, with maximum effect at 2–4 weeks. Visible jawline slimming develops over 4–8 weeks as muscle bulk reduces.

The treatment experience

Consultation

A thorough assessment includes detailed medical and dental history, palpation of masticatory muscles to assess tenderness and hypertrophy, assessment of jaw opening range and any clicking or crepitus, evaluation of tooth wear patterns, and discussion of stress and sleep factors. We may also recommend dental assessment if malocclusion or significant tooth damage is suspected.

The Procedure

Treatment is typically performed without anaesthesia (the injections are well-tolerated), taking approximately 10–15 minutes. Patients are asked to clench repeatedly during injection to confirm accurate muscle targeting. Ice may be applied afterwards to minimise bruising.

Aftercare and Follow-Up

Post-treatment guidance includes avoiding hard or chewy foods for 24 hours, avoiding lying flat for 4 hours, gentle jaw exercises as directed, and review at 4 weeks to assess response and determine if top-up is needed. Most patients establish a treatment cycle of every 3–6 months, with some finding that intervals gradually lengthen as chronic muscle tension resolves.

Combined medical and aesthetic benefits

One of the unique aspects of masseter botulinum toxin treatment is its dual benefit. Patients seeking medical relief from bruxism often notice and appreciate the aesthetic jawline slimming, whilst those presenting for facial slimming may experience unexpected relief from jaw tension and headaches.

A survey published in Aesthetic Surgery Journal (2023) found that 78% of patients treated for bruxism rated the aesthetic improvement as an important secondary benefit, whilst 65% of patients treated for aesthetic jawline slimming reported meaningful improvement in jaw tension symptoms.

When botulinum toxin is not enough

While effective for many patients, botulinum toxin is not a comprehensive solution for all TMJ disorders. Patients may also benefit from custom occlusal splints for sleep bruxism, physiotherapy for joint mobilisation and postural correction, stress management techniques and cognitive behavioural therapy, and pharmacological management for pain or sleep disorders. Complex TMJ cases involving disc displacement, degenerative joint disease, or structural abnormalities may require referral to a maxillofacial specialist.

Key Takeaways

• Botulinum toxin is an evidence-based treatment for bruxism and TMJ-related myofascial pain
• Treatment reduces masseter force, promotes muscle atrophy, and modulates pain signalling
• Clinical trials show 45–65% reduction in pain scores and 30–40% reduction in muscle thickness
• The dual medical-aesthetic benefit (pain relief plus jawline slimming) is valued by patients
• Comprehensive management may require additional modalities alongside injectable treatment